中国未感染人群新冠疫苗接种有效性及覆盖率:一项基于社区的回顾性队列研究
该研究基于2023年1月13日至2月9日北京线上问卷的45,344名未感染新冠居民,分析真实世界疫苗有效性与衰减效应。同源加强和异源加强针对感染的疫苗有效性分别为11%和23%,老年人获益最大;加强接种12个月后出现衰减效应。高风险人群接种覆盖率较低,作者建议优先提高该人群接种率并定期加强接种。
要点
- 同源加强和异源加强针对感染的疫苗有效性分别为11%和23%,老年人获益最大。
- 青少年加强接种覆盖率较低,未发现显著疫苗有效性。
- 加强接种组在接种后12个月出现衰减效应,作者建议12个月内定期加强接种。
核心结论
- 高风险和脆弱人群接种覆盖率低可能导致巨大疾病和社会负担,应优先提高这些群体的疫苗覆盖率。
- 由于免疫衰减,应在12个月内安排定期加强接种。
研究设计与样本
- 2023年1月13日至2月9日在中国北京开展线上问卷调查的社区基于回顾性队列研究,共纳入45,344名符合条件的未感染新冠受访者。
- 按年龄(18岁以下、18-59岁、60岁以上)和健康状况(有基础疾病、过敏、癌症、免疫缺陷或器官移植)分组分析疫苗接种和感染状态。
- 采用倾向性评分匹配和有序逻辑回归检验不同新冠疫苗类型、接种策略的有效性及衰减效应。
主要发现
- 样本人群感染率为82.42%。
- 疫苗接种率为94.70%,其中23.73%完成基础免疫系列,68.54%完成同源加强接种,2.43%完成异源加强接种;高风险人群接种覆盖率较低。
- 同源加强和异源加强针对感染的真实世界疫苗有效性分别为11%和23%,老年人获益最大。
- 青少年加强接种覆盖率较低,未发现显著疫苗有效性。
- 不同疫苗类型间无显著差异,加强接种组在接种后12个月发现衰减效应。
临床怎么用
- 作者认为应优先提高高风险和脆弱人群的疫苗覆盖率。
- 作者建议由于免疫衰减,应在12个月内安排定期加强接种。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The COVID-19 vaccination coverage rate is notably high among the Chinese population; however, as China eased its zero-COVID policy in November 2022, the pandemic outbreak has imposed a substantial burden on Chinese society. This study aims to analyze real-world vaccination effectiveness and waning effects among community-based COVID-19 infection-naive individuals in China and among different sub-groups. METHODS: An online questionnaire survey was conducted in Beijing, China, from January 13th to February 9th, 2023 and a total of 45,344 eligible respondents were included in the analysis. Vaccination and infection status among different groups classified by age (under 18, 18-59, and over 60) and health conditions (having underlying disease, allergy, cancer, immune deficiency or organ transplant) were analyzed. Propensity score matching and ordered logistic regression were used to examine the effectiveness of different COVID-19 vaccine types, vaccination strategies and the waning effects. RESULTS: The infection rate was 82.42 % among sampled population. The vaccination rate was 94.70 %, with 23.73 % of them completed primacy vaccination series, 68.54 % completed homogenous booster vaccination and 2.43 % completed heterogenous booster vaccination; however, the high-risk population had a lower vaccination coverage. Results showed that real-world vaccine effectiveness (VE) of homogenous and heterogenous booster vaccination against infection were 11 % and 23 %, respectively, and the elderly benefited the most. Adolescents had a lower booster vaccination coverage and no significant VE was identified. No significant differences were observed among different vaccine types, and waning effects were identified in the booster vaccination group 12 months post-vaccination. CONCLUSIONS: Low vaccination coverage among high-risk and vulnerable may lead to a huge disease and societal burden, thus improving vaccine coverage of these groups should be prioritized. In addition, due to waning immunity, regular booster vaccination should be scheduled within 12 months.
引用
- Fu Y, Xu Z, Wang Q, et al. Effectiveness and coverage of COVID-19 vaccination among the infection-naive population: A community-based retrospective cohort study in China. Vaccine. 2025. PMID: 39923544. doi:10.1016/j.vaccine.2025.126836
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。